BR112017002575B1 - Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo - Google Patents

Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo Download PDF

Info

Publication number
BR112017002575B1
BR112017002575B1 BR112017002575-2A BR112017002575A BR112017002575B1 BR 112017002575 B1 BR112017002575 B1 BR 112017002575B1 BR 112017002575 A BR112017002575 A BR 112017002575A BR 112017002575 B1 BR112017002575 B1 BR 112017002575B1
Authority
BR
Brazil
Prior art keywords
individual
lymphocyte
level
sample
blood sample
Prior art date
Application number
BR112017002575-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017002575A2 (pt
Inventor
Joseph M. Ahearn
Chau-Ching Liu
Susan M. Manzi
Original Assignee
Allegheny Singer Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allegheny Singer Research Institute filed Critical Allegheny Singer Research Institute
Publication of BR112017002575A2 publication Critical patent/BR112017002575A2/pt
Publication of BR112017002575B1 publication Critical patent/BR112017002575B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
BR112017002575-2A 2014-08-08 2015-08-07 Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo BR112017002575B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462035073P 2014-08-08 2014-08-08
US62/035,073 2014-08-08
PCT/US2015/044372 WO2016023006A1 (en) 2014-08-08 2015-08-07 Anti-lymphocyte autoantibodies as diagnostic biomarkers

Publications (2)

Publication Number Publication Date
BR112017002575A2 BR112017002575A2 (pt) 2018-01-30
BR112017002575B1 true BR112017002575B1 (pt) 2023-11-07

Family

ID=55264686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002575-2A BR112017002575B1 (pt) 2014-08-08 2015-08-07 Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo

Country Status (7)

Country Link
US (1) US9709564B2 (enExample)
EP (1) EP3177930A1 (enExample)
JP (1) JP2017528734A (enExample)
CN (1) CN107110861A (enExample)
BR (1) BR112017002575B1 (enExample)
RU (1) RU2017107273A (enExample)
WO (1) WO2016023006A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6674543B2 (ja) 2015-07-31 2020-04-01 アレゲーニー・シンガー リサーチ インスティチュート 抗体に基づく薬物のコンパニオン診断としての細胞結合補体活性化産物アッセイ
KR101674018B1 (ko) * 2016-05-16 2016-11-08 (주)글로리바이오텍 Cd4, cd8 세포 정보를 이용한 hiv 진단 방법
CA3022850A1 (en) 2016-05-24 2017-11-30 Allegheny-Singer Research Institute Methods and systems using c4 gene copy number and cell-bound complement activation products for identification of lupus and pre-lupus
EP4217744A4 (en) * 2020-09-28 2024-11-06 Allegheny Singer Research Institute METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1756571T3 (da) * 2004-04-09 2010-12-13 Univ Pittsburgh Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
AU2005242719B2 (en) * 2004-05-11 2011-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Diagnosing and monitoring inflammatory diseases by measuring complement components on white blood cells
CA2738952A1 (en) * 2008-10-16 2010-04-22 Cypress Bioscience, Inc. Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases
WO2011099012A1 (en) * 2010-02-12 2011-08-18 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus (sle)
EP2673644B1 (en) * 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
CN102818890A (zh) * 2011-06-10 2012-12-12 苏州卫生职业技术学院 一种检测系统性红斑狼疮患者自身抗体的方法
PT2791675T (pt) * 2011-12-13 2018-07-27 Baxalta Inc Medição de autoanticorpos em condições de baixa condutividade
US20150204866A1 (en) * 2012-08-02 2015-07-23 Sense Proteomic Limited Auto-antigen biomarkers for lupus
WO2014093268A1 (en) * 2012-12-10 2014-06-19 Allegheny-Singer Research Institute Methods and systems for using complement-tagged molecules as biomarkers of disease
JP6400604B2 (ja) 2013-02-08 2018-10-03 アレゲーニー・シンガー リサーチ インスティチュート プレループス診断用バイオマーカーとしての細胞結合性補体活性産物
CN103439517A (zh) * 2013-09-11 2013-12-11 河北省健海生物芯片技术有限责任公司 一种系统性红斑狼疮自身抗体检测装置

Also Published As

Publication number Publication date
JP2017528734A (ja) 2017-09-28
US20160041164A1 (en) 2016-02-11
BR112017002575A2 (pt) 2018-01-30
WO2016023006A1 (en) 2016-02-11
RU2017107273A3 (enExample) 2019-01-18
US9709564B2 (en) 2017-07-18
EP3177930A1 (en) 2017-06-14
CN107110861A (zh) 2017-08-29
RU2017107273A (ru) 2018-09-10

Similar Documents

Publication Publication Date Title
Vrbensky et al. The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta‐analysis of a diagnostic test
Turesson et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis
Benzimra et al. Acute rejection
Macchi et al. Anti‐platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia
Kelton et al. A prospective comparison of four techniques for measuring platelet‐associated IgG
Demir et al. Usefulness of in vivo and in vitro diagnostic tests in the diagnosis of hypersensitivity reactions to quinolones and in the evaluation of cross-reactivity: a comprehensive study including the latest quinolone gemifloxacin
Liu et al. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus
Araújo et al. Oxidative stress markers correlate with renal dysfunction and thrombocytopenia in severe leptospirosis
Porretti et al. Implementation and outcomes of a transfusion-related acute lung injury surveillance programme and study of HLA/HNA alloimmunisation in blood donors
Lee et al. A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia
BR112017002575B1 (pt) Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo
Liu et al. Detection and analysis of autoantigens targeted by autoantibodies in immunorelated pancytopenia
Al-Mughales Immunodiagnostic Significance of Anti‐RA33 Autoantibodies in Saudi Patients with Rheumatoid Arthritis
Shao et al. Predictive value of serum procalcitonin for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study
JP2007537449A (ja) 白血球上の補体成分を測定することによる炎症性疾患の診断およびモニタリング
Sachs et al. Screening of multiparous women to avoid transfusion‐related acute lung injury: a single centre experience
Peng et al. Comparison of physical crossmatch and virtual crossmatch to identify preexisting donor-specific human leukocyte antigen (HLA) antibodies and outcome following kidney transplantation
JP5144950B2 (ja) ナチュラルキラー活性の評価方法
Alwar et al. Clinical patterns and hematological spectrum in autoimmune hemolytic anemia
Smith et al. T lymphocyte responses to nonpolymorphic HLA-derived peptides are associated with chronic renal allograft dysfunction
Tomer et al. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool
JP2016513251A (ja) プレループス診断用バイオマーカーとしての細胞結合性補体活性産物
Tomicic et al. Alloimmune neonatal neutropenia in Croatia during the 1998–2008 period
Hong et al. Evaluating high fluorescence lymphocyte count as a predictor of severe dengue infection
Joutsi‐Korhonen et al. Glycoprotein V‐specific platelet‐associated antibodies in thrombocytopenic patients

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ALLEGHENY SINGER RESEARCH INSTITUTE (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/08/2015, OBSERVADAS AS CONDICOES LEGAIS